← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Alector, Inc. (ALEC) 10-Year Financial Performance & Capital Metrics

ALEC • • Industrial / General
HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative
AboutAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Show more
  • Revenue $101M +3.6%
  • EBITDA -$136M +4.7%
  • Net Income -$119M +8.7%
  • EPS (Diluted) -1.23 +21.2%
  • Gross Margin 100% +10.0%
  • EBITDA Margin -135.4% +8.0%
  • Operating Margin -144.19% +7.8%
  • Net Margin -118.39% +11.9%
  • ROE -91.24% -22.0%
  • ROIC -92.62% +17.8%
  • Debt/Equity 0.34 +15.6%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 36.5%
  • ✓Trading at only 1.4x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Shares diluted 15.4% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y36.5%
3Y-21.4%
TTM12.26%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM31.99%

EPS CAGR

10Y-
5Y-
3Y-
TTM37.36%

ROCE

10Y Avg-27.99%
5Y Avg-28.1%
3Y Avg-27.88%
Latest-36.84%

Peer Comparison

Alzheimer's & Neurodegenerative
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ANVSAnnovis Bio, Inc.84.81M3.20-0.00-189.15%
CLNNClene Inc.60.19M5.11-0.90-47.71%-142.5%-17.38%
ABOSAcumen Pharmaceuticals, Inc.112.67M1.86-1.09-143.12%0.16
BHVNBiohaven Ltd.1.58B11.92-1.28-198.83%0.09
IKTInhibikase Therapeutics, Inc.200.09M1.65-1.42-100%-65.37%0.00
ALECAlector, Inc.198.66M1.82-1.483.6%-156.03%-186.68%0.34
CGTXCognition Therapeutics, Inc.121.82M1.38-1.62-76.61%0.04
ATHEAlterity Therapeutics Limited60M3.31-2.9035.32%-330.63%-73.75%0.00

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+416K3.73M27.68M21.22M21.1M207.09M133.62M97.06M100.56M
Revenue Growth %-7.98%6.41%-0.23%-0.01%8.82%-0.35%-0.27%0.04%
Cost of Goods Sold+13.67M29.91M73.03M100.53M156.87M189.41M08.85M0
COGS % of Revenue32.87%8.01%2.64%4.74%7.44%0.91%-0.09%-
Gross Profit+-13.26M-26.18M-45.35M-79.31M-135.77M17.68M133.62M88.21M100.56M
Gross Margin %-31.87%-7.01%-1.64%-3.74%-6.44%0.09%1%0.91%1%
Gross Profit Growth %--0.97%-0.73%-0.75%-0.71%1.13%6.56%-0.34%0.14%
Operating Expenses+15.55M36.41M84.97M35.09M59.4M55.04M271.45M239.95M245.56M
OpEx % of Revenue37.38%9.75%3.07%1.65%2.82%0.27%2.03%2.47%2.44%
Selling, General & Admin1.87M6.5M11.93M33.94M59.4M55.04M61.03M56.69M59.62M
SG&A % of Revenue4.5%1.74%0.43%1.6%2.82%0.27%0.46%0.58%0.59%
Research & Development13.67M29.91M73.03M100.53M156.87M189.41M210.42M192.12M185.94M
R&D % of Revenue32.87%8.01%2.64%4.74%7.44%0.91%1.57%1.98%1.85%
Other Operating Expenses22K199K5.04M-99.37M-156.87M-189.41M0-8.85M0
Operating Income+-15.13M-32.68M-57.29M-114.4M-195.17M-37.36M-137.83M-151.74M-145M
Operating Margin %-36.38%-8.75%-2.07%-5.39%-9.25%-0.18%-1.03%-1.56%-1.44%
Operating Income Growth %--1.16%-0.75%-1%-0.71%0.81%-2.69%-0.1%0.04%
EBITDA+-14.93M-32M-56.27M-110.63M-187.91M-29.05M-129.36M-142.89M-136.16M
EBITDA Margin %-35.89%-8.57%-2.03%-5.21%-8.91%-0.14%-0.97%-1.47%-1.35%
EBITDA Growth %--1.14%-0.76%-0.97%-0.7%0.85%-3.45%-0.1%0.05%
D&A (Non-Cash Add-back)201K680K1.02M3.77M7.26M8.31M8.47M8.85M8.84M
EBIT-15.13M-32.68M-57.29M-113.25M-195.17M-37.36M-137.83M-151.74M-145M
Net Interest Income+000000000
Interest Income000000000
Interest Expense000000000
Other Income/Expense22K199K5.04M9.02M4.95M1.03M7.78M26.56M26.08M
Pretax Income+-15.11M-32.48M-52.25M-105.39M-190.23M-36.33M-130.06M-125.18M-118.92M
Pretax Margin %-36.32%-8.7%-1.89%-4.97%-9.02%-0.18%-0.97%-1.29%-1.18%
Income Tax+0000003.25M5.21M128K
Effective Tax Rate %1%1%1%1%1%1%1.03%1.04%1%
Net Income+-15.11M-32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M
Net Margin %-36.32%-8.7%-1.89%-4.97%-9.02%-0.18%-1%-1.34%-1.18%
Net Income Growth %--1.15%-0.61%-1.02%-0.81%0.81%-2.67%0.02%0.09%
Net Income (Continuing)-15.11M-32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-1.78-0.63-0.76-1.62-2.45-0.45-1.62-1.56-1.23
EPS Growth %-0.65%-0.21%-1.13%-0.51%0.82%-2.6%0.04%0.21%
EPS (Basic)-1.78-0.63-0.76-1.62-2.45-0.45-1.62-1.56-1.23
Diluted Shares Outstanding8.5M51.22M68.37M61.73M77.76M80.42M82.47M83.73M96.59M
Basic Shares Outstanding8.5M51.22M68.37M61.73M77.76M80.42M82.47M83.73M96.59M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+51.19M232.97M293.18M357.44M421.51M749.71M726.43M565.81M424.82M
Cash & Short-Term Investments50.84M32.45M290.41M353.07M413.31M735.25M712.85M548.86M413.4M
Cash Only50.84M32.45M65.47M89.64M49.97M329.15M154.32M74.56M33.02M
Short-Term Investments00224.94M263.43M363.34M406.1M558.53M474.31M380.38M
Accounts Receivable218K200.24M0007.39M2.59M00
Days Sales Outstanding191.2719.57K---13.037.07--
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets002.77M000016.95M11.42M
Total Non-Current Assets+2.92M3.09M15.18M64.48M66.74M64.94M61.21M56.02M43.49M
Property, Plant & Equipment2.54M2.83M10.94M62.33M62.65M57.9M53.33M47.06M37.1M
Fixed Asset Turnover0.16x1.32x2.53x0.34x0.34x3.58x2.51x2.06x2.71x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments200K01.47M000000
Other Non-Current Assets184K252K2.77M2.15M4.09M7.05M7.88M8.96M6.39M
Total Assets+54.11M236.06M308.36M421.91M488.25M814.66M787.65M621.83M468.3M
Asset Turnover0.01x0.02x0.09x0.05x0.04x0.25x0.17x0.16x0.21x
Asset Growth %-3.36%0.31%0.37%0.16%0.67%-0.03%-0.21%-0.25%
Total Current Liabilities+1.51M27.4M13.04M61.97M68.09M139.56M93.81M177.95M125.06M
Accounts Payable1.15M1.14M126K278K3M4.75M4.19M3.77M2.21M
Days Payables Outstanding30.7513.910.631.016.999.15-155.73-
Short-Term Debt000000000
Deferred Revenue (Current)01000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities05.6M9.56M5.73M7.29M11.66M12.76M54.74M54.55M
Current Ratio33.90x8.50x22.48x5.77x6.19x5.37x7.74x3.18x3.40x
Quick Ratio33.90x8.50x22.48x5.77x6.19x5.37x7.74x3.18x3.40x
Cash Conversion Cycle---------
Total Non-Current Liabilities+77.51M260.69M392.71M165.2M152.63M374.38M479.4M309.72M216.44M
Long-Term Debt000000009.39M
Capital Lease Obligations00041.47M43.74M39.81M35.27M30.46M24.38M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities77.51M77.54M7.57M493K472K158K759K68.42M10.51M
Total Liabilities79.02M288.09M405.76M227.17M220.72M513.93M573.21M487.67M341.5M
Total Debt+00048.04M51.26M47.6M43.33M38.92M42.52M
Net Debt-50.84M-32.45M-65.47M-41.6M1.29M-281.55M-111M-35.64M9.5M
Debt / Equity---0.25x0.19x0.16x0.20x0.29x0.34x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage---------
Total Equity+-24.91M-52.03M-97.4M194.74M267.53M300.72M214.44M134.16M126.8M
Equity Growth %--1.09%-0.87%3%0.37%0.12%-0.29%-0.37%-0.05%
Book Value per Share-2.93-1.02-1.423.153.443.742.601.601.31
Total Shareholders' Equity-24.91M-52.03M-97.4M194.74M267.53M300.72M214.44M134.16M126.8M
Common Stock01K1K7K8K8K8K8K9K
Retained Earnings-29.71M-62.19M-114.44M-219.82M-410.05M-446.38M-579.69M-710.08M-829.13M
Treasury Stock00193.44M000000
Accumulated OCI-300K-980K-42K142K614K-943K-4.58M184K261K
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-12.99M-17.77M127.46M-99.31M-166.73M298.55M-20.33M-184.16M-229.91M
Operating CF Margin %-31.23%-4.76%4.61%-4.68%-7.9%1.44%-0.15%-1.9%-2.29%
Operating CF Growth %--0.37%8.17%-1.78%-0.68%2.79%-1.07%-8.06%-0.25%
Net Income-15.11M-32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M
Depreciation & Amortization201K680K1.02M5.57M7.26M8.31M8.47M8.85M8.84M
Stock-Based Compensation1.96M5.35M6.92M030.52M40.78M042.8M39.46M
Deferred Taxes000000000
Other Non-Cash Items1.88M6.78M-2.59M12.78M929K2.1M44.98M-15.27M-12.17M
Working Capital Changes-47K8.68M174.36M-12.27M-15.22M283.68M59.53M-90.15M-146.99M
Change in Receivables-218K-20K238K00-7.39M4.8M2.59M0
Change in Inventory-560K6.58M2.45M000000
Change in Payables708K-41K-809K152K2.41M1.92M-572K-377K-1.44M
Cash from Investing+-2.25M-801K-224.12M-48.87M-105.05M-49.66M-159.01M101.92M107.13M
Capital Expenditures-2.25M-801K-1.88M-15.27M-5.03M-3.25M-4.12M-2.38M-1.25M
CapEx % of Revenue5.41%0.21%0.07%0.72%0.24%0.02%0.03%0.02%0.01%
Acquisitions---------
Investments---------
Other Investing00-222.24M0-100.02M0000
Cash from Financing+-77K-15K131.15M172.35M232.11M30.3M4.51M2.55M81.54M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing-77K-15K131.15M07.51M30.3M001.04M
Net Change in Cash---------
Free Cash Flow+-15.24M-18.57M125.58M-114.57M-171.77M295.3M-24.45M-186.54M-231.16M
FCF Margin %-36.64%-4.97%4.54%-5.4%-8.14%1.43%-0.18%-1.92%-2.3%
FCF Growth %--0.22%7.76%-1.91%-0.5%2.72%-1.08%-6.63%-0.24%
FCF per Share-1.79-0.361.84-1.86-2.213.67-0.30-2.23-2.39
FCF Conversion (FCF/Net Income)0.86x0.55x-2.44x0.94x0.88x-8.22x0.15x1.41x1.93x
Interest Paid000000000
Taxes Paid000000000

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)----216.52%-82.3%-12.79%-51.75%-74.81%-91.24%
Return on Invested Capital (ROIC)-----69.38%-19.46%-168.61%-112.7%-92.62%
Gross Margin-3187.02%-700.83%-163.87%-373.76%-643.53%8.54%100%90.88%100%
Net Margin-3632.21%-869.61%-188.78%-496.65%-901.64%-17.54%-99.77%-134.34%-118.39%
Debt / Equity---0.25x0.19x0.16x0.20x0.29x0.34x
FCF Conversion0.86x0.55x-2.44x0.94x0.88x-8.22x0.15x1.41x1.93x
Revenue Growth-797.84%641.02%-23.33%-0.57%881.54%-35.48%-27.36%3.6%

Revenue by Segment

2021
Phase Three License173.4M
Phase Three License Growth-

Frequently Asked Questions

Growth & Financials

Alector, Inc. (ALEC) reported $69.0M in revenue for fiscal year 2024. This represents a 16498% increase from $0.4M in 2016.

Alector, Inc. (ALEC) grew revenue by 3.6% over the past year. Growth has been modest.

Alector, Inc. (ALEC) reported a net loss of $107.7M for fiscal year 2024.

Dividend & Returns

Alector, Inc. (ALEC) has a return on equity (ROE) of -91.2%. Negative ROE indicates the company is unprofitable.

Alector, Inc. (ALEC) had negative free cash flow of $197.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.